Baqyiattalah University of Medical Science
Tehran, Iran
NCT Number: NCT00676377
Postoperative ileus (POI) in the absence of any mechanical obstruction remains a commonly encountered clinical problem.So, this study aimed to show the effective way to decrease the rate of postoperative Ileus (POI).
Looking for future studies?
Notify Me18 year–76 year
All sexes
Interventional
Phase 4
Tehran, Iran
We honestly declare that, the use of parasympathomimetic agents such as neostigmine is not without risk. Patients with underlying bradyarrhythmias or those receiving β-adrenergic antagonists may be more susceptible to neostigmine-induced bradycardia. Similarly, neostigmine increases airway secretions and bronchial reactivity, which may exacerbate active bronchospasm. Recently, a new class of drugs-peripherally acting mu-opioid receptor antagonists-may help enhance multimodal management of POI. Although, the cost benefit of the new class of drugs is debated. It has been suggested that the individual components of multimodal protocols-for example, laparoscopy-may reduce certain post surgical morbidities (including POI) But do not by them prevent POI. Therefore, combinations of strategies with demonstrated effectiveness-early feeding , epidural analgesia, laparoscopic surgery, and use of peripherally acting mu-opioid-receptor antagonists-may help transform the reactive approach to POI into a proactive multimodal paradigm that effectively targets the diverse etiologic factors leading to this common clinical problem.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
Other names: Neostigmine Group
Saline Placebo
Other names: Placebo Group
Time frame: 6 hours
Time frame: 3 hours
Baqiyatallah Medical Sciences University
Other
A New Approach of Neostigmine in Unavoidable Post Operative Ileus After Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07248098
Digestive System Diseases, Gastrointestinal Diseases
Adana, Saricam, Turkey (Türkiye)
View Trial DetailsNCT05985343
Digestive System Diseases, Gastrointestinal Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT04405037
Digestive System Diseases, Gastrointestinal Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT05298774
Digestive System Diseases, Gastrointestinal Diseases
New Haven, Connecticut, United States
View Trial Details